{"id":617,"date":"1998-07-01T12:01:00","date_gmt":"1998-07-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/inhibitoren-der-catechol-o-methyltransferase-verbessern-effekte-von-levodopa-beim-morbus-parkinson"},"modified":"2022-03-17T14:08:51","modified_gmt":"2022-03-17T13:08:51","slug":"inhibitoren-der-catechol-o-methyltransferase-verbessern-effekte-von-levodopa-beim-morbus-parkinson","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/inhibitoren-der-catechol-o-methyltransferase-verbessern-effekte-von-levodopa-beim-morbus-parkinson","title":{"rendered":"Inhibitoren der Catechol-O-Methyltransferase verbessern Effekte von Levodopa beim Morbus Parkinson"},"content":{"rendered":"<p>Im Lancet (1998, 351, 1221) erschien k\u00fcrzlich ein kurzer Artikel von J.G. Nutt aus Portland, Oregon, \u00fcber ein neues pharmakologisches Prinzip, die Wirkungsdauer von Levodopa (L-DOPA) beim M. Parkinson zu verl\u00e4ngern. Der Rigor beim M. Parkinson ist durch Dopamin-Mangel in bestimmten Himstamm-Arealen bedingt. L-DOPA, das im Gehirn in Dopamin umgewandelt wird, ist zwar wirksam, die [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im Lancet (1998, 351, 1221) erschien k\u00fcrzlich ein kurzer Artikel von J.G. Nutt aus Portland, Oregon, \u00fcber ein neues pharmakologisches Prinzip, die Wirkungsdauer von Levodopa (L-DOPA) beim M. Parkinson zu verl\u00e4ngern. Der Rigor beim M. Parkinson ist durch Dopamin-Mangel in bestimmten Himstamm-Arealen bedingt. L-DOPA, das im Gehirn in Dopamin umgewandelt wird, ist zwar wirksam, die [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1436,1434,615,1435,1437,1433,595,1432,629,665,1438,1439,1431],"class_list":["post-617","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-anti-parkinson-mittel","tag-benserazid","tag-bromocriptin","tag-carbidopa","tag-catechol-o-methyltransferase-hemmer","tag-comt-hemmer","tag-dihydroxyphenylalanin","tag-entacapon","tag-l-dopa","tag-levodopa","tag-m-parkinson","tag-parkinson-syndrom","tag-tolcapon"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=617"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/617\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}